WebAdding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and chemotherapy prolongs the survival of men with metastatic hormone-sensitive prostate cancer (mHSPC), results from a new trial show. Data from the global randomized, phase 3 ARASENS trial demonstrate that patients assigned to ... WebJun 20, 2024 · In summary, triplet therapy may be a viable option for men with mHSPC who would otherwise have been offered ADT plus docetaxel. The benefits of triplet therapy over ADT plus an ASI remain questionable, …
National Center for Biotechnology Information
WebPlanning treatment based on mHSPC disease progression1 ADT monotherapy Triplet therapy (ADT + DOC + ARPI) ADT + androgen receptor pathway inhibitors (ARPI) ADT + … WebFeb 14, 2024 · Occupational therapy is a science-driven, evidence-based profession that enables people of all ages to participate in daily living or live life to the fullest. Patients often see occupational ... ride on mower picture
Die Triple-Therapie des mHSPC – urotube
WebOct 9, 2024 · APCCC 2024: “Triplet Therapy” for Metastatic Hormone-Sensitive Prostate Cancer, (ADT + Docetaxel + Additional Systemic Therapy) (UroToday.com) In this session, … WebJun 3, 2024 · mHSPC: Metastatic hormone-sensitive prostate cancer CRPC: Castration-resistant prostate cancer OS: Overall survival EOD: Extent of disease value MRI: Magnetic resonance imaging CT: Computed tomography FDG-PET/CT: 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography LHRH: Luteinizing hormone … WebJun 15, 2024 · The requirement for concomitant use of steroids alongside systemic therapy for mHSPC needs to be discussed with the patient. As an inhibitor of cytochrome P450 17A1 (CYP17) and 17α-hydroxylase, abiraterone blocks androgen synthesis and glucocorticoid production, leading to decreased cortisol levels . Decreased cortisol levels can result in an ... ride on mower racing australia